Steve Reed. Interviewed by Charlotte Schubert.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 19898441.
- Also identified by DOI 10.1038/nbt1109-971.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Steve Reed believes the organization he has founded has the potential to radically increase the developing world's access to vaccines for neglected diseases. The efforts of the Seattle-based Infectious Disease Research Institute (IDRI), which operates as a not-for-profit biotech company, may start to pay off during the H1N1 'swine' flu pandemic. IDRI developed an adjuvant to boost the effectiveness and supplies of flu vaccines and is making the technology available to vaccine manufacturers in developing nations. Charlotte Schubert talks to Reed about how IDRI, a 90-person operation with a $19 million annual budget, could have such a big impact.
Medical subject headings
- Adjuvants, Immunologic
- Vaccines